WHO's Mpox Emergency: Profits Over Public Health Dangers
Submitted by MAGA
Posted 98 days ago
**Pandemic Profiteering? Vaccine Makers Celebrate as WHO Declares Mpox Emergency**
In a startling move, the World Health Organization (WHO) has declared the Mpox outbreak in Africa a Public Health Emergency of International Concern (PHEIC).
This decision comes as pharmaceutical companies reap the rewards of skyrocketing stock prices amid growing fears of a global health crisis.
As reported, shares for prominent vaccine manufacturers surged following the WHO's announcement.
Bavarian Nordic, a leading producer of the JYNNEOS vaccine, saw its share price jump nearly 18% overnight.
The company claims it has 300,000 doses ready for distribution and the capacity to produce 10 million more by the end of next year.
This spike in share prices raises critical questions regarding the motivations behind declaring a public health emergency.
Was this decision genuinely made for the sake of public health or is it merely a guise for profit maximization by big pharmaceutical companies?
The narrative surrounding Mpox is not new.
Historically known as monkeypox, the disease predominantly affected marginalized communities in Africa.
Yet, it rarely made international headlines until its transmission was identified among specific demographics during the outbreaks in 2022-2023.
Now, with the emergence of a new variant, Mpox threatens to disrupt health across multiple continents.
As WHO experts echo warnings of a disastrous pandemic scenario, the potential for mass vaccination campaigns looms large, raising alarm bells among critics of health authority decisions.
Many advocates for local governance and public health reform argue that prioritizing responses driven by pharmaceutical interests over community-based solutions risks exacerbating existing health disparities.
This sentiment is echoed by those who think the global health apparatus is overly reliant on a profit-driven model that prioritizes pharmaceutical gains over effective health outcomes.
As international travel has resumed post-pandemic, fears of a widespread Mpox outbreak are understandably rising.
However, one must not ignore the lessons learned from recent history regarding handling public health emergencies.
A skeptical public increasingly views government and pharmaceutical partnerships through a critical lens.
Moving forward, the focus should be on ensuring health strategies genuinely benefit those most affected by these outbreaks, rather than simply serving to fuel corporate profit margins.
The public deserves transparency and accountability from both health organizations and drug companies during these times of crisis.
The Biden administration's response will be closely monitored by concerned citizens who demand more effective and ethical health strategies in the face of potential pandemics.
As the Mpox outbreak develops, one can only hope that the fight against this virus doesn’t merely turn into another chapter of "pandemic profiteering."
Sources:
americafirstreport.com
independentsentinel.com
euronews.com
In a startling move, the World Health Organization (WHO) has declared the Mpox outbreak in Africa a Public Health Emergency of International Concern (PHEIC).
This decision comes as pharmaceutical companies reap the rewards of skyrocketing stock prices amid growing fears of a global health crisis.
As reported, shares for prominent vaccine manufacturers surged following the WHO's announcement.
Bavarian Nordic, a leading producer of the JYNNEOS vaccine, saw its share price jump nearly 18% overnight.
The company claims it has 300,000 doses ready for distribution and the capacity to produce 10 million more by the end of next year.
This spike in share prices raises critical questions regarding the motivations behind declaring a public health emergency.
Was this decision genuinely made for the sake of public health or is it merely a guise for profit maximization by big pharmaceutical companies?
The narrative surrounding Mpox is not new.
Historically known as monkeypox, the disease predominantly affected marginalized communities in Africa.
Yet, it rarely made international headlines until its transmission was identified among specific demographics during the outbreaks in 2022-2023.
Now, with the emergence of a new variant, Mpox threatens to disrupt health across multiple continents.
As WHO experts echo warnings of a disastrous pandemic scenario, the potential for mass vaccination campaigns looms large, raising alarm bells among critics of health authority decisions.
Many advocates for local governance and public health reform argue that prioritizing responses driven by pharmaceutical interests over community-based solutions risks exacerbating existing health disparities.
This sentiment is echoed by those who think the global health apparatus is overly reliant on a profit-driven model that prioritizes pharmaceutical gains over effective health outcomes.
As international travel has resumed post-pandemic, fears of a widespread Mpox outbreak are understandably rising.
However, one must not ignore the lessons learned from recent history regarding handling public health emergencies.
A skeptical public increasingly views government and pharmaceutical partnerships through a critical lens.
Moving forward, the focus should be on ensuring health strategies genuinely benefit those most affected by these outbreaks, rather than simply serving to fuel corporate profit margins.
The public deserves transparency and accountability from both health organizations and drug companies during these times of crisis.
The Biden administration's response will be closely monitored by concerned citizens who demand more effective and ethical health strategies in the face of potential pandemics.
As the Mpox outbreak develops, one can only hope that the fight against this virus doesn’t merely turn into another chapter of "pandemic profiteering."
Sources:
americafirstreport.com
independentsentinel.com
euronews.com
Latest News